N
GBT

Natixis’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Natixis’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-176,600
Closed -$12M – 1422
2022
Q3 		$12M Sell
176,600
-160,400
-48% -$8.85M 0.06% 248
2022
Q2 		$10.8M Sell
337,000
-267,200
-44% -$7.82M 0.04% 282
2022
Q1 		$20.9M Buy
604,200
+162,620
+37% +$4.86M 0.07% 253
2021
Q4 		$12.9M Buy
441,580
+59,645
+16% +$1.85M 0.04% 329
2021
Q3 		$9.73M Buy
381,935
+103,955
+37% +$3.06M 0.03% 377
2021
Q2 		$9.73M Buy
+277,980
New +$10.9M 0.04% 281
2017
Q2 		– Sell
-54,815
Closed -$2.02M – 1021
2017
Q1 		$2.02M Buy
+54,815
New +$1.38M 0.03% 308

Other funds holding GBT

BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Natixis's GBT Position: Q4 2022 in Review

Natixis sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2022, closing a stake of 176,600 shares — an estimated $12M sold.

Natixis first reported a position in GBT in Q1 2017 and held it in 7 quarters. The position peaked at $20.9M in Q1 2022. 2 funds tracked by Wall St. Rank hold GBT as of Q4 2022.

  • Natixis reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2022 after selling out during the quarter.
  • Natixis sold 176,600 Global Blood Therapeutics, Inc. shares in Q4 2022, an estimated $12M.
  • Natixis first reported a position in Global Blood Therapeutics, Inc. in Q1 2017 and held it in 7 quarters.
  • Natixis's Global Blood Therapeutics, Inc. position peaked at $20.9M in Q1 2022.
  • 2 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2022.

Based on Natixis's 13F filing for Q4 2022, filed 13 Feb 2023.